Skip to main content
SpringerLink
Log in

Marqueurs pronostiques et prédictifs des cancers du sein précoces

  • Chapter
Diagnostic et décision dans le cancer du sein à un stade précoce

Part of the book series: Collection Oncologie Pratique ((ONCOLPRAT))

  • 313 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–53: 6

    Article  Google Scholar 

  2. Van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009

    Article  PubMed  Google Scholar 

  3. Buyse M, Loi S, van’t Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183–119 vv2

    Article  PubMed  CAS  Google Scholar 

  4. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207–219

    Article  PubMed  CAS  Google Scholar 

  5. Press MF, Bernstein L, Thomas PA et al (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894–2904

    PubMed  CAS  Google Scholar 

  6. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1–22

    Article  PubMed  CAS  Google Scholar 

  7. Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63: 181–7

    Article  PubMed  CAS  Google Scholar 

  8. Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287–5312

    Article  PubMed  CAS  Google Scholar 

  9. Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer Ann Oncol 20: 1319–29

    Article  PubMed  CAS  Google Scholar 

  10. Oakman C, Bessi S, Zafarana E et al (2009) Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 11: 205

    Article  PubMed  Google Scholar 

  11. Bullwinkel J, Baron-Lühr B, Lüdemann A et al (2006) Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol Mar 206 (3): 624–35

    Article  CAS  Google Scholar 

  12. Rahmanzadeh R, Hüttmann G, Gerdes J, Scholzen T (2007) Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif 40: 422–430

    Article  PubMed  CAS  Google Scholar 

  13. Beresford MJ, Wilson GD, Makris A (2006) Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 8: 216

    Article  PubMed  Google Scholar 

  14. Jones RL, Salter J, A’Hern R et al (2009) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116: 53–68

    Article  PubMed  CAS  Google Scholar 

  15. Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174–83

    Article  PubMed  CAS  Google Scholar 

  16. Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and progosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736–50

    Article  PubMed  CAS  Google Scholar 

  17. de Azambuja E, Cardoso F, de Castro G, et al (2007) Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96: 1504–13

    Article  PubMed  Google Scholar 

  18. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32 825 patients. Breast 17: 323–34

    Article  PubMed  CAS  Google Scholar 

  19. Colozza M, Sidoni A, Piccart-Gebhart M (2010) Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol 11: 414–5

    Article  PubMed  Google Scholar 

  20. Penault-Llorca F, Andre F, Sagan C et al (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27: 2809–15

    Article  PubMed  CAS  Google Scholar 

  21. Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognosic and predictive potential. Lancet Oncol 11: 174–83

    Article  PubMed  CAS  Google Scholar 

  22. Von Minckwitz G, Sinn Hp, Raab G et al (2008) Clinical response after two cycles compared dto HER2, Ki67, p53 and bcl2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10: R30

    Article  Google Scholar 

  23. Moasser MM (2007) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26: 6577–92

    Article  PubMed  CAS  Google Scholar 

  24. Sauter G, Lee J, Barlett JM et al (2009) Guidelines for human epidermal growth factor receptor2 testing: biologic and methodologic considerations. J Clin Oncol 27: 1323–33

    Article  PubMed  CAS  Google Scholar 

  25. Guarneri V, Barbieri E, Dieci MV et al (2010) Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev. 36: S62–66

    Article  PubMed  CAS  Google Scholar 

  26. Pritchard KI, Shepherd LE, O’Malley FP (2006) National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103–11

    Article  PubMed  CAS  Google Scholar 

  27. Pritchard KI, Messersmith H, Elavathil L (2008) HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26: 736–44

    Article  PubMed  CAS  Google Scholar 

  28. Knoop AS, Knudsen H, Balslev E et al (2005) Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil. J Clin Oncol 23: 7483–90

    Article  PubMed  CAS  Google Scholar 

  29. Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11: 6598–6607

    Article  PubMed  CAS  Google Scholar 

  30. Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496–1506

    Article  PubMed  CAS  Google Scholar 

  31. Gennari A, Sormani MP, Pronzato P et al (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100: 14–20

    Article  PubMed  CAS  Google Scholar 

  32. Leary AF, Hanna WM, van de Vijver MJ (2009) Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 27: 1694–1705

    Article  PubMed  CAS  Google Scholar 

  33. Järvinen TA, Tanner M, Bärlund M et al (1999) Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26: 142–50

    Article  PubMed  Google Scholar 

  34. Slamon DJ, Romond EH, Perez EA (2006) Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol 4: 4–9

    Google Scholar 

  35. O’Malley FP, Chia S, Tu D et al (2009) Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101: 644–50

    Article  PubMed  Google Scholar 

  36. Tubbs R, Barlow WE, Budd GT et al (2009) Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27: 3881–6

    Article  PubMed  CAS  Google Scholar 

  37. Press MF, Sauter G, Buyse M et al (2010) Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-besed chemotherapy j Clin Oncol dec 28 [Epub ahead of print]

    Google Scholar 

  38. Flaman JM, Frebourg T, Moreau V et al (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 9: 3963–7

    Article  Google Scholar 

  39. Aas T, Børresen AL, Geisler S et al (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811–4

    Article  PubMed  CAS  Google Scholar 

  40. Geisler S, Lønning PE, Aas T et al (2001) Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505–12

    PubMed  CAS  Google Scholar 

  41. Di Leo A, Tanner M, Desmedt C et al (2007) p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 18: 997–1003.

    Article  PubMed  Google Scholar 

  42. Bertheau P, Turpin E, Rickman DS et al (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin cyclophosphamide regimen. PLoS Med 4: e90

    Article  PubMed  Google Scholar 

  43. Lehmann-Che J, André F, Desmedt C et al (2010) Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 15: 246–52

    Article  PubMed  CAS  Google Scholar 

  44. Wagner P, Wang B, Clark E et al (2005) Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 4: 1149–52

    Article  PubMed  CAS  Google Scholar 

  45. Pentheroudakis G, Kalogeras KT, Wirtz RM et al (2009) Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial Breast Cancer Res Treat 116: 131–43

    Article  PubMed  CAS  Google Scholar 

  46. Andre F, Hatzis C, Anderson K et al (2008) Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer Clin cancer res 13: 2061–67

    Article  Google Scholar 

  47. Ozanne EM, Braithwaite D, Sepucha K et al (2009) Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol 27: 214–9

    Article  PubMed  Google Scholar 

  48. De Cremoux P, Grandin L, Diéras V et al (2009) Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Res 29: 1475–82

    PubMed  Google Scholar 

  49. Look M, van Putten W, Duffy M et al (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116–28

    Article  PubMed  CAS  Google Scholar 

  50. Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406: 747–52

    Article  PubMed  CAS  Google Scholar 

  51. Wirapati P, Sotiriou C, Kunkel S et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hôpital Saint Louis, Unité d’oncologie moléculaire, Université Paris — Diderot, Hôpital Saint-Louis, 1, avenue Claude Vellefaux, 75010, Paris, France

    Patricia de Cremoux

Authors
  1. Patricia de Cremoux
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag France, Paris

About this chapter

Cite this chapter

de Cremoux, P. (2012). Marqueurs pronostiques et prédictifs des cancers du sein précoces. In: Diagnostic et décision dans le cancer du sein à un stade précoce. Collection Oncologie Pratique. Springer, Paris. https://doi.org/10.1007/978-2-8178-0253-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0253-4_3

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0252-7

  • Online ISBN: 978-2-8178-0253-4

Publish with us

Policies and ethics

Search

Navigation